Dispensing prescription drugs in 3-month supplies reduces drug costs by a thirdNovember 20, 2009Purchasing prescription drugs in a three-month supply rather than a one-month supply has long been regarded as a way to reduce the cost of drugs for patients and third-party payers. New research from the University of Chicago quantifies the savings for the first time. An analysis of 26,852 prescriptions filled for 395 different drugs from 2000-2005 showed that patients who purchased their drugs in three-month supplies rather than with one-month supplies saved on average 29% in out-of-pocket costs. After factoring in third-party payers, including Medicare, Medicaid and insurance companies, total savings averaged 18%. "These savings may not seem large to some, but they could help trim the cost of health care, which is especially important given the nationwide debate about how to finance health care reform," said G. Caleb Alexander, MD, MS, Assistant Professor of Medicine at the University of Chicago Medical Center and senior author of the study, which will be published in print November 20, 2009, in Applied Health Economics & Health Policy. Although prescription drug costs represent only about 10% of the nation's total health care bill, they are one of the fastest growing sectors and affect a large proportion of patients. "No matter what any health care reform package looks like, millions of Americans are burdened by prescription drugs costs, and this is one important way to help relieve that burden," Alexander said. "Other methods to lower prescription drug costs include substituting generic drugs for brand-name drugs and discontinuing non-essential medicines." The drugs in this study were limited to those that were prescribed for common chronic conditions, including high cholesterol, hypertension, hypothyroidism and depression. Only patients who received both a one-month supply and a three-month supply during the same year in the same dose and quantity were included in the main analyses. Forty-four percent of the prescriptions examined were dispensed in three-month supplies; the remainder were dispensed in one-month supplies. "This indicates that there is a significant amount of cost savings yet to be realized by converting from one-month supplies to three-month supplies," Alexander said. The average monthly out-of-pocket cost for a one-month supply was $20.44 compared with $15.10 for a three-month supply yielding a 29% savings after adjustment for potential confounders. The corresponding numbers for the average monthly total costs were $42.72 and $37.95, respectively, yielding an 18% savings after adjustment for potential confounders. If all the drugs in the study had been provided as three-month supplies, the out-of-pocket savings would have amounted to an estimated $148.6 million. Total savings would have amounted to $245.1 million. All figures are in 2005 dollars. Patients' sex, race, level of education and number of chronic conditions did not seem to predict who was most likely to fill a 3-month supply, Alexander said. "We were surprised to find that there were no substantial systematic differences in the characteristics of individuals filling one-month and three-month supplies." "Patients who are paying a lot each month for medicines-especially to treat chronic conditions-should investigate whether they can save money by using a three-month supply," he said. "Physicians need to keep this in mind as a potent way to help patients afford their medications." University of Chicago Medical Center |
|||||||||||||||||||||
| Related Prescription Drugs Current Events and Prescription Drugs News Articles Women with gout at greater risk of heart attack than men Women with gout are at greater risk of a heart attack than men with the disease, indicates research published ahead of print in the Annals of the Rheumatic Diseases. Higher opioid dose linked to overdose risk in chronic pain patients More and more Americans with chronic pain not caused by cancer are taking medically prescribed opioids like Oxycontin (oxycodone) and Vicodin (hydrocodone). Costs of psoriasis treatments outpace inflation Findings from a cost model suggest that expenses for systemic psoriasis therapy appear to be increasing at a faster rate than inflation, and newer biologically derived treatments are more expensive than traditional systemic therapies. UCSF study finds African-Americans bear disproportionate burden of smoking costs in California African Americans comprise six percent of the California adult population, yet they account for over eight percent of the state's smoking-attributable health care expenditures and 13 percent of smoking-attributable mortality costs, according to a new analysis by UCSF researchers. Fancier fakes: Makers of bogus prescription drugs pose new challenges Manufacturers of counterfeit prescription drugs are embracing new tactics to deal with an estimated $75-billion-year market in knockoffs, a battle that is far from being won. Pain management failing as fears of prescription drug abuse rise Millions of Americans with significant or chronic pain associated with their medical problems are being under-treated as physicians increasingly fail to provide comprehensive pain treatment - either due to inadequate training, personal biases or fear of prescription drug abuse. Deaths related to narcotic pain relievers have doubled since 1991: Study Deaths from opioid use in Ontario have doubled-from 13.7 deaths per million residents in 1991 to 27.2 deaths per million residents in 2004-according to a new study led by physicians at St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES) in Toronto. Is cannabis the answer to Booze Britain's problems? Substituting cannabis in place of more harmful drugs may be a winning strategy in the fight against substance misuse. Free e-samples of prescription drugs: At what cost? Search the Internet to learn about your asthma, high cholesterol or other common disorder, and odds are you'll be directed to a pharmaceutical company-sponsored Web homepage. Despite some benefit, drug ads can be harmful to your health While the debate over prescription drug advertising persists, a new study released online in the American Journal of Public Health offers guidelines for improving drug ads in order to minimize potential harm and maximize benefits. More Prescription Drugs Current Events and Prescription Drugs News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||